EUVIMEDEUVIMED entdecken
Crossref

Semiparametric piecewise accelerated failure time model for the analysis of immune-oncology clinical trials

Hisato Sunami iD, Satoshi Hattori iD

Biometrics · 2026

DOI: 10.1093/biomtc/ujaf171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biometrics, 2026. Verfasst von Hisato Sunami und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Statistics, Graduate School of Medicine, The University of Osaka, 2-2, Yamadaoka, Suita City, Osaka 565-0871, Japan. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Models, Statistical, Neoplasms, Immunotherapy. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Grant-in-Aid for Scientific Research, Ministry of Education, Science, Sports and Technology of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Effectiveness of immune-oncology chemotherapies has been presented in recent clinical trials. The Kaplan-Meier estimates of the survival functions of the immune therapy and the control often suggested the presence of the lag-time until the immune therapy began to act. It implies the use of hazard ratio under the proportional hazards assumption would not be appealing, and many alternatives have been investigated such as the restricted mean survival time. In addition to such overall summary of the treatment contrast, the lag-time is also an important feature of the treatment effect. Identical survival functions up to the lag-time implies patients who are likely to die before the lag-time would not benefit the treatment and identifying such patients would be very important. We propose the semiparametric piecewise accelerated failure time model and its inference procedure based on the semiparametric maximum likelihood method. It provides not only an overall treatment summary, but also a framework to identify patients who have less benefit from the immune-therapy in a unified way. Numerical experiments confirm that each parameter can be estimated with minimal bias. Through a real data analysis, we illustrate the evaluation of the effect of immune-oncology therapy and the characterization of covariates in which patients are unlikely to receive the benefit of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicModels, StatisticalNeoplasmsImmunotherapyHumansComputer SimulationSurvival AnalysisProportional Hazards ModelsLikelihood FunctionsBiometryKaplan-Meier Estimate

Stichwörter der Autor:innen

accelerated failure time modelimmune-oncology clinical trialsproportional hazardsemiparametric estimationsurvival tree

Autor:innen und Institutionen

  • Department of Biomedical Statistics, Graduate School of Medicine, The University of Osaka, 2-2, Yamadaoka, Suita City, Osaka 565-0871, Japan.
  • Department of Biomedical Statistics, Graduate School of Medicine, and Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary ResearchInitiatives (OTRI), The University of Osa…

ORCID-Profile: Hisato Sunami, Satoshi Hattori

Förderung

  • Grant-in-Aid for Scientific Research
  • Ministry of Education, Science, Sports and Technology of Japan

Zitieren

APA

Sunami, H., & Hattori, S. (2026). Semiparametric piecewise accelerated failure time model for the analysis of immune-oncology clinical trials. Biometrics. https://doi.org/10.1093/biomtc/ujaf171

Vancouver

Sunami H, Hattori S. Semiparametric piecewise accelerated failure time model for the analysis of immune-oncology clinical trials. Biometrics. 2026. doi:10.1093/biomtc/ujaf171

BibTeX
@article{Sunami2026,
  author = {Sunami, Hisato and Hattori, Satoshi},
  title = {Semiparametric piecewise accelerated failure time model for the analysis of immune-oncology clinical trials},
  journal = {Biometrics},
  year = {2026},
  doi = {10.1093/biomtc/ujaf171}
}
Kostenlos starten →